INTRODUCTION
============

The socio-economic burden due to the rapidly increasing number of elderly people with asthma is of concern in aging societies. The clinical characteristics of asthma in the elderly are different from those of young adults. Moreover, in the elderly, a combination of a poor perception of asthma symptoms and multiple comorbidities may make rapid diagnosis and treatment difficult. For this reason, the rates of hospitalization and mortality due to asthma are higher in the elderly than in other age groups \[[@B1][@B2]\], and the burden of asthma has increased.

Despite ongoing research, the pathophysiology and the risk factors of asthma in the elderly are not yet fully understood, and the literature concerning the effects of risk factor control on asthma outcomes in the elderly is limited.

Previously, we evaluated the risk factors to predict asthma exacerbation in elderly people with asthma and our results indicated that a state of depression, low cognitive function, poor proficiency in using inhaler devices, poor medication adherence, and a previous history of asthma exacerbations at baseline were important risk factors \[[@B3]\]. In addition, the absence of a caregiver and a micronutrient deficiency (magnesium and vitamin D) were also found to be risk factors for asthma exacerbations in elderly with asthma \[[@B4]\]. On the basis of these results, we designed multifaceted interventions to improve risk factors for asthma exacerbation, and aimed to examine their effects on asthma outcomes in the elderly with asthma.

MATERIALS AND METHODS
=====================

Study design
------------

We established a prospective multicenter cohort study with planned 5-year follow-up (2008--2013) in Korea \[[@B3]\] in which approximately 1,000 patients had been recruited from 9 referral hospitals. We conducted subgroup analysis every year and this study was performed at the fifth year of cohort study as a single-arm interventional study with historical controls. A total of 100 subjects were selected from our cohort study and patient selection was randomized using an online random number generator ([www.random.org](http://www.random.org)). All participants were aged 65 years or older and had a history of asthma exacerbation within the last 3 years. The diagnosis of asthma was made by immunology physicians, based on a clinical history and the documented presence of a reversible airway obstruction: a positive bronchodilator response or ≥ 12% and 200-mL improvement in forced expiratory volume in 1 second (FEV~1~) after antiasthmatic treatment \[[@B5]\].

Baseline assessment at recruitment included sex, age, asthma control status, body mass index, smoking status, atopy, the Korean version of asthma control test (ACT) score \[[@B6]\], medication adherence, cognitive function and mood states, proficiency in using inhaler devices, and a history of previous exacerbations, as described in previous studies \[[@B3][@B5]\]. The predicted percentage values for FEV~1~ (FEV~1~ %pred) and forced vital capacity (FVC %pred) were obtained using the Morris methods \[[@B7]\]. Serum magnesium levels were measured using colorimetry methods, and the reference range was 1.5--2.5 mg/dL.

Multifaceted interventions
--------------------------

The patients were treated by allergic physicians according to the Global Initiative for Asthma guidelines \[[@B8]\], and received multifaceted interventions to target known risk factors associated with asthma exacerbation. Our multifaceted approach included repeated education on asthma and on improving inhaler techniques for patients and their caregivers, provision of an action plan to manage acute exacerbations, a brief message service to avoid losses to follow-up, and oral magnesium replacement therapy (48-mg tablet, 2 tablets 3 times daily). The participants with abnormal renal function or serum magnesium level higher than normal range (\>3.0 mg/dL) were excluded from magnesium replacement therapy.

The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (approval number: 1205-083-410) and we received informed consent from all patients.

Outcomes
--------

The primary outcome for the multifaceted intervention efficacy was evaluated as an acute asthma exacerbation rate compared to the rate 12 months previously. The patients were requested to visit the clinic at regular 3-month intervals, over a total follow-up period of 12 months. At every visit, any occurrence of asthma exacerbation over the previous 3 months was checked. An asthma exacerbation was recorded when one of the following criteria was reported: (1) the use of systemic corticosteroids, or an increase in the stable maintenance dose for at least 3 days; (2) unscheduled visits to the outpatient clinic; and (3) hospitalization or an emergency department visit, due to an asthma attack.

The secondary outcomes were lung function improvement and the ACT score, and both were reviewed at each visit, according to the original cohort protocol. We compared the value of the baseline with that of the last visit.

Statistical analysis
--------------------

The groups were compared using the *t* test, the Mann-Whitney *U* test, the chi-square test, or the Kruskal-Wallis test. A comparison of the asthma exacerbation rate for the current year and the year prior was performed using McNemar test. All statistical analyses were undertaken using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). A *p* value of \< 0.05 was considered statistically significant.

RESULTS
=======

The baseline characteristics of the study participants are presented in [Table 1](#T1){ref-type="table"}. The mean age was 73.8 years, and female patients comprised 48% of the study population. Sixty one patients (62.2%) were diagnosed with asthma when aged over 65 years. A total of 8 patients (8%) were lost to follow-up, mainly due to consent withdrawal.

###### Baseline characteristics (n = 100)

![](apa-8-e1-i001)

  Characteristic                        Value               
  ------------------------------------- ------------------- --------------
  Age (yr)                              73.8 ± 4.9          
  Female sex                            47 (47.0)           
  Body mass index (kg/m^2^)             23.5 ± 2.9          
  Asthma diagnosis \> 65 yr             61/98 (62.2)        
  Smoking                                                   
                                        Never smoker        57/99 (57.6)
                                        Ex-smoker           32/99 (32.3)
                                        Current smoker      10/99 (10.1)
  Pulmonary function                                        
                                        FEV~1~ %pred        74.5 ± 25.2
                                        FVC %pred           83.7 ± 21.1
                                        FEV~1~/FVC          67.9 ± 12.5
  PNS abnormalities                     61/99 (61.6)        
  MBPT positivity                       80/93 (86.0)        
                                        PC~20~ (mg/mL)      6.9 ± 6.4
  Peripheral eosinophils counts (/µL)   326.9 ± 273.6       
  Sputum eosinophil (%)                 8.4 ± 10.3          
  Total IgE (IU/mL)                     198.9 ± 327.3       
  ACT score                             20.9 ± 4.2          
  Micronutrients                                            
                                        Magnesium (mg/dL)   2.2 ± 0.2

Values are presented as mean ± standard deviation or number (%).

FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PNS, paranasal sinuses; MBPT, methacholine bronchial provocation test; PC~20~, provocative concentration of methacholine in a 20% fall in FEV~1~; ACT, asthma control test.

Analysis for the primary outcome indicated that 46 events of acute asthma exacerbations occurred in 46 patients and the exacerbation rate (46 of 92, 50.0%) was significantly lower than that of the previous year (67 of 100, 67.0%) (*p* \< 0.001) ([Fig. 1](#F1){ref-type="fig"}).

![Acute exacerbations before and after multifaceted interventions. AE+, patients with acute exacerbations; AE-, patients without acute exacerbations.](apa-8-e1-g001){#F1}

Analysis for the secondary outcome showed that lung function test measurements, evaluated as FEV~1~ %pred and FVC %pred, improved significantly after multifaceted interventions (*p* = 0.004, and *p* = 0.036, respectively). However, there was no difference in the ACT score either pre-, or postinterventions ([Fig. 2](#F2){ref-type="fig"}).

![Change of lung functions and symptom score according to the interventions. FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; ACT, asthma control test; NS, not statistically significant.](apa-8-e1-g002){#F2}

Among 100 participants, 67 patients (67%) had experienced acute asthma exacerbations in the previous 12 months. There was no significant difference in the baseline characteristics except for lung functions and ACT score between the 2 groups with or without asthma exacerbations during the previous 12 months ([Table 2](#T2){ref-type="table"}). In the current study, acute exacerbations occurred in 42 patients (66.7%) in the group with prior acute exacerbations and in 4 patients (13.8%) in the group without prior acute exacerbations (*p* \< 0.001). The history of acute exacerbations in the previous 12 months correlated significantly with the recurrence of acute exacerbations.

###### Characteristics between groups with or without exacerbation in the previous year

![](apa-8-e1-i002)

  Characteristic                        With exacerbation (n = 67)   Without exacerbation (n = 33)   *p* value      
  ------------------------------------- ---------------------------- ------------------------------- -------------- -----------
  Age (yr)                              73.3 ± 4.4                   73.8 ± 6.0                      0.290          
  Female sex                            34 (50.7)                    13 (39.4)                       0.196          
  Body mass index (kg/m^2^)             23.2 ± 2.9                   23.9 ± 2.8                      0.289          
  Asthma diagnosis \> 65 yr             40 (59.7)                    23 (69.7)                       0.297          
  Smoking                                                                                            0.797          
                                        Never smoker                 38 (56.7)                       19/32 (59.4)   
                                        Ex-smoker                    22 (32.8)                       10/32 (31.3)   
                                        Current smoker               7 (10.4)                        3/32 (9.4)     
  Pulmonary function                                                                                                
                                        FEV~1~ %pred                 71.4 ± 27.2                     81.5 ± 18.7    0.037^\*^
                                        FVC %pred                    80.7 ± 22.7                     90.4 ± 15.0    0.014^\*^
                                        FEV~1~/FVC                   67.1 ± 13.9                     69.7 ± 8.8     0.274
  PNS abnormalities                     41 (61.2)                    20/32 (62.5)                    0.541          
                                        PC~20~ (mg/mL)               6.3 ± 6.5                       7.9 ± 6.5      0.322
  Peripheral eosinophils counts (/µL)   308.4 ± 391.7                346.9 ± 612.8                   0.728          
  Sputum eosinophil (%)                 9.4 ± 11.0                   6.6 ± 8.7                       0.362          
  Total IgE (IU/mL)                     154.0 ± 189.5                322.3 ± 558.9                   0.430          
  ACT score                             19.6 ± 4.5                   23.6 ± 1.2                      \<0.001^\*^    
  Micronutrients                                                                                                    
                                        Magnesium (mg/dL)            3.0 ± 5.4                       2.3 ± 0.2      0.670

Values are presented as mean ± standard deviation or number (%).

FEV~1~, forced expiratory volume in 1 second; FVC, Forced vital capacity; PNS, paranasal sinuses; PC~20~, provocative concentration of methacholine in a 20% fall in FEV~1~; ACT, asthma control test.

^\*^*p* \< 0.05, statistically significant differences.

Among 92 participants who completed the study, only 60 patients (65.2%) continued with the magnesium supplement therapy. The reasons given for discontinuation of magnesium therapy were as follows: 8 patients (25%) reported taking too many medications, 7 patients (21.9%) reported adverse reactions, 5 (15%) withdrew from magnesium therapy voluntarily, 4 (12.5%) reported aggravation of a disease other than asthma, and 8 (25%) reported other reasons. Nausea and diarrhea were the common adverse reactions of magnesium supplement therapy. When analyzing the correlation between the magnesium supplement and asthma exacerbations, a significantly lower asthma exacerbation rate was observed in the group with continuous magnesium supplement compared to the group without magnesium supplement (41.6% vs. 65.6%, *p* = 0.029). Moreover, there was significant improvement in FEV~1~ %pred and FVC %pred in the group with continuous magnesium supplement (FEV~1~ %pred: from 79.6 ± 23.7 to 87.1 ± 20.0, *p* = 0.008, and FVC %pred: from 82.9 ± 25.4 to 91.8 ± 20.6, *p* = 0.047). However, no difference in the ACT score was observed between the groups.

DISCUSSION
==========

Until recently, the well-known risk factors or predictors associated with asthma exacerbations in the elderly were smoking, obesity, combined chronic obstructive pulmonary disease, poor asthma control, poor adherence and proficiency in relation to inhaled corticosteroid (ICS) therapy, depression, and cognitive dysfunction \[[@B1][@B9][@B10][@B11]\]. The absence of a caregiver was also found to be a risk factor for asthma exacerbations in elderly participants with asthma in our study (unpublished data), and a recent study has shown that physical performance should be considered as a predictor of asthma exacerbations \[[@B12]\]. Considering these results, a multifaceted approach is needed to improve asthma outcomes in the elderly.

Some studies have examined the effects of risk factor control in the elderly, however the results have not been consistent. In a Japanese study on elderly patients with asthma, caregiver assistance in using ICS therapy effectively improved lung function \[[@B13]\]. In contrast, an American study providing standard educational information and instructions concerning peak flow meter use and asthma action plans failed to improve asthma outcomes in the elderly \[[@B14]\]. Therefore, in elderly patients with asthma, assistance from caregivers appears to be an important component to enhance the effects of education and treatment. The presence of caregivers can be effective in compensating for the negative effect of depression and cognitive dysfunction, which are both very common in elderly patients with asthma. Depression and impaired cognitive function have been associated with poor proficiency and adherence to ICS medication \[[@B15]\]. As such, caregivers may provide important support in maintaining regular medication use. In our study, we also provided repeated education on asthma and inhaler techniques for patients and their caregivers. We consider this to be one reason why we were able to improve asthma outcomes.

Inadequate nutrition is prevalent in the elderly due to tooth loss, impaired digestive function, multiple comorbidities and medications, decreased physical activity, and low income \[[@B16]\]. Previously, we have published data on serum micronutrient levels and the clinical characteristics of elderly study participants with asthma, and showed that lower serum magnesium levels were significantly related to a history of asthma exacerbation \[[@B4]\]. Similarly, one study has reported that lower serum magnesium correlated with more severe asthma, and that magnesium deficiency caused increased bronchial hypersensitivity and airway muscle contraction \[[@B17]\]. On the basis of these results, we provided oral magnesium supplements to the participants in the present study. We observed a significant decrease in the asthma exacerbation rate and an increased lung function in the magnesium supplement group. We consider these results represent the correction of a micronutrient deficiency that could decrease future asthma exacerbations in the elderly. However, 35% of patients failed to continue oral magnesium therapy for varying reasons, which may indicate difficulty in the general use of magnesium supplement therapy. Several studies have reported that nutritional education for caregivers or patients was effective in improving the nutritional status of elderly patients \[[@B18][@B19]\]. The improvement plan of adherence to medication and a tailored nutritional education program for the elderly should be considered in a future study.

In this study, a history of acute exacerbations in the previous year was a major predictor of future exacerbations and this is consistent with other literature \[[@B3][@B20]\]. Therefore, it is important to be alert concerning elderly with asthma who have a history of prior acute exacerbations, and to aim to prevent further exacerbations through an active multifaceted intervention.

The limitations of this study involve the relatively small study population, the short intervention period and no control arm. A larger randomized controlled study is needed to clarify the efficacy of multifaceted interventions in the elderly.

Nevertheless, given limited data available on the effect of controlling risk factors to prevent an acute exacerbation in a multifaceted way in the elderly with asthma, this study is useful and confirms the need for further targeted research in this area.

In summary, to reduce acute exacerbations in the elderly with asthma, a multifaceted approach to increase medical awareness, proficiency and adherence to inhaler therapy, assistance of caregivers, and correction of micronutrients deficiency is likely to be effective.
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